

LUD 5538.1 CIP (09807339)

- Claim 111. (Previously presented) The isolated nucleic acid molecule of claim 110, selected from the group consisting of the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 5, 6, 7 and 8.
- Claim 112. (Currently amended) [Expression] An isolated expression vector comprising the isolated nucleic acid molecule of claim 110, operably linked to a promoter.
- Claim 113. (Currently amended) [Expression] An isolated expression vector comprising the isolated nucleic acid molecule of claim 111, operably linked to a promoter.
- Claim 114. (Currently amended) [Recombinant] An isolated recombinant cell comprising the isolated expression vector of claim 112.
- Claim 115. (Currently amended) [Recombinant] An isolated recombinant cell comprising the isolated expression vector of claim 113.
- Claim 116. (Currently amended) [Recombinant] An isolated recombinant cell comprising the isolated nucleic acid molecule of claim 110.
- Claim 117. (Currently amended) [Recombinant] An isolated recombinant cell comprising the isolated nucleic acid molecule of claim 111.
- Claim 118. (Currently amended) [Recombinant] The isolated recombinant cell of claim 114, further comprising an expression vector which contains a nucleic acid molecule encoding a cytokine, operably linked to a promoter.
- Claim 119. (Currently amended) [Recombinant] The isolated recombinant cell of claim 115, further comprising an expression vector which contains a nucleic acid molecule encoding a cytokine, operably linked to a promoter.
- Claim 120. (Currently amended) [Recombinant] The isolated recombinant cell of claim 116, further comprising a nucleic acid molecule which encodes a cytokine.
- Claim 121. (Currently amended) [Recombinant] The isolated recombinant cell of claim 117, further comprising a nucleic acid molecule which encodes a cytokine.

LUD 5538.1 CIP (09807339)

Claim 122. (Currently amended) The isolated recombinant cell of claim 118, 119, 120 or 121 wherein said cytokine is interleukin.

Claim 123. (Currently amended) The isolated recombinant cell of claim 122, wherein said interleukin is IL-2, IL-4, or IL-12.

Claim 124. (Currently amended) The isolated recombinant cell of claim 114, 115, 116 or 117, wherein said recombinant cell is a eukaryotic cell.

Claims 125-127. (Canceled)

Claim 128: (Currently amended) Expression system useful in making a recombinant cell, comprising:

(i) a first isolated vector which encodes the protein encoded by the isolated nucleic acid molecule of claim 110 or 111, and

(ii) a second isolated vector which either (a) encodes an MHC or HLA molecule, or (b) encodes an interleukin.

Claims 129-130. (Canceled)

Claim 131: (Previously presented) Kit useful in determining expression of a cancer associated antigen, comparing a separate portion of each of (i) the nucleotide sequences defined by SEQ ID NOS: 9 and 10, (ii) the nucleotide sequences defined by SEQ ID NOS: 11 and 12, and (iii) the nucleotide sequences defined by SEQ ID NOS: 13 and 14.

Claim 132: (Previously presented) The isolated nucleic acid molecule of claim 110, which encodes the protein encoded by SEQ ID NO: 5.

Claim 133: (Previously presented) The isolated nucleic acid molecule of claim 110, which encodes the protein encoded by SEQ ID NO: 6.

Claim 134. (Canceled)

LUD 5538.1 CIP (09807339)

- Claim 135: (Previously presented) The isolated nucleic acid molecule of claim 110, which encodes the protein encoded by SEQ ID NO: 8.
- Claim 136: (Previously presented) The isolated nucleic acid molecule of claim 110, comprising SEQ ID NO: 5.
- Claim 137: (Previously presented) The isolated nucleic acid molecule of claim 110, comprising SEQ ID NO: 6.
- Claim 138: (Previously presented) The isolated nucleic acid molecule of claim 110, comprising SEQ ID NO: 7.
- Claim 139: (Previously presented) The isolated nucleic acid molecule of claim 110, comprising SEQ ID NO: 8.
- Claim 140: (Previously presented) The isolated nucleic acid molecule of claim 110, consisting of SEQ ID NO: 7.
- Claim 141. (Canceled)
- Claim 142. (Previously presented) The isolated nucleic acid molecule of claim 110, consisting of SEQ ID NO: 7.
- Claims 143-144. (Canceled)
- Claim 145. (Currently amended) A composition [useful in treating a subject afflicted with a cancer,] comprising the isolated recombinant cell of claim 125, and a pharmaceutically acceptable adjuvant.
- Claim 146. (Currently amended) The composition of claim 145, wherein said isolated recombinant cell expresses an HLA or MHC molecule.
- Claim 147. (Currently amended) The composition of claim 145, wherein said isolated recombinant cell is an isolated [a] recombinant human cell.

LUD 5538.1 CIP (09807339)

- Claim 148. (Previously presented) An isolated nucleic acid molecule consisting of a nucleotide sequence as set forth in SEQ ID NO: 9, 10, 11, 12, 13, or 14.
- Claim 149. (Previously presented) Kit useful in determining expression of a cancer associated antigen, comprising (i) nucleic acid molecules consisting of the nucleotide sequences set forth in SEQ ID NOS: 9 and 10, (ii) nucleic acid molecules consisting of the nucleotide sequences set forth in SEQ ID NOS: 11 and 12, and (iii) nucleic acid molecules consisting of the nucleotide sequences set forth in SEQ ID NOS: 13 and 14, wherein (i), (ii) and (iii) are presented in separate container means in said kit.
- Claim 150. (Currently amended) A composition comprising [a] an isolated expression vector, wherein said isolated expression vector encodes [one or more peptides] a peptide, wherein [each of] said [peptides] peptide consists of 8 to 25 amino acids[, wherein said 8 to 25 amino acids] which are present in consecutive order in the protein encoded by the isolated nucleic acid molecule of claim 110, and a pharmaceutically acceptable carrier.
- Claim 151. (Currently amended) The composition of claim 150, [wherein said] comprising a plurality of isolated expression vectors, each of which encodes a peptide consisting of 8 to 25 amino acids which are present in consecutive order in the protein encoded by the isolated nucleic acid molecule of claim 110, and a pharmaceutically acceptable carrier [encodes a plurality of peptides].

REMARKS

On January 31, 2003, Applicants had an interview with the Examiner. The Examiner indicated that the claims presented in the amendment hand-delivered on February 3, 2003, would be allowable.

The Examiner did not act on the amendment for 7 months. There were two status request phone calls, one of which was ignored, and the other of which resulted in the Examiner indicating that the claims were allowable.